JP2024510610A5 - - Google Patents

Info

Publication number
JP2024510610A5
JP2024510610A5 JP2023555828A JP2023555828A JP2024510610A5 JP 2024510610 A5 JP2024510610 A5 JP 2024510610A5 JP 2023555828 A JP2023555828 A JP 2023555828A JP 2023555828 A JP2023555828 A JP 2023555828A JP 2024510610 A5 JP2024510610 A5 JP 2024510610A5
Authority
JP
Japan
Prior art keywords
nucleic acid
alphavirus
seq
synthetic
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510610A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/020881 external-priority patent/WO2022198002A1/en
Publication of JP2024510610A publication Critical patent/JP2024510610A/ja
Publication of JP2024510610A5 publication Critical patent/JP2024510610A5/ja
Pending legal-status Critical Current

Links

JP2023555828A 2021-03-19 2022-03-18 人工アルファウイルス由来ｒｎａレプリコン発現系 Pending JP2024510610A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163163475P 2021-03-19 2021-03-19
US63/163,475 2021-03-19
PCT/US2022/020881 WO2022198002A1 (en) 2021-03-19 2022-03-18 Artificial alphavirus-derived rna replicon expression systems

Publications (2)

Publication Number Publication Date
JP2024510610A JP2024510610A (ja) 2024-03-08
JP2024510610A5 true JP2024510610A5 (https=) 2025-01-06

Family

ID=83285087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555828A Pending JP2024510610A (ja) 2021-03-19 2022-03-18 人工アルファウイルス由来ｒｎａレプリコン発現系

Country Status (9)

Country Link
US (2) US11613561B2 (https=)
EP (1) EP4308136A4 (https=)
JP (1) JP2024510610A (https=)
KR (1) KR20230159500A (https=)
CN (1) CN117083071A (https=)
AU (1) AU2022238403A1 (https=)
CA (1) CA3211496A1 (https=)
IL (2) IL319926A (https=)
WO (1) WO2022198002A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL319926A (en) * 2021-03-19 2025-05-01 Tiba Biotech Llc Alphavirus-derived artificial RNA replicon expression systems
CN116218889A (zh) * 2022-12-13 2023-06-06 浙江大学 一种表达猫细小病毒VP2蛋白的mRNA疫苗及其制备方法
CN118147171B (zh) * 2024-03-08 2024-12-06 上海复诺健生物科技有限公司 具有增强的外源基因表达水平的自扩增mRNA核酸序列
CN118726273B (zh) * 2024-07-08 2025-06-03 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 一种促进口蹄疫病毒复制的高效培养基的制备
JP7657411B1 (ja) * 2025-01-23 2025-04-07 医療法人すぎやま内科 乳がん細胞の増殖抑制剤及び乳がん治療剤

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US20030170871A1 (en) * 2000-04-25 2003-09-11 Chiron Corporation Alphavirus-based vectors for persistent infection
US20030232324A1 (en) * 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
JP4608210B2 (ja) * 2001-05-31 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キメラアルファウイルスレプリコン粒子
US7442381B2 (en) * 2003-03-20 2008-10-28 Alphavax, Inc. Alphavirus replicons and helper constructs
CN1989250B (zh) * 2004-05-18 2013-11-20 阿尔法瓦克斯公司 Tc-83衍生的甲病毒属载体、颗粒和方法
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
WO2014170493A2 (en) 2013-04-19 2014-10-23 Novartis Ag Alphavirus vector
CA2945736A1 (en) 2014-05-04 2015-11-12 Forrest Innovations Ltd. Compositions for mosquito control and uses of same
WO2017053851A1 (en) 2015-09-23 2017-03-30 Massachusetts Institute Of Technology Compositions and methods for modified dendrimer nanoparticle vaccine delivery
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
US10385319B2 (en) * 2016-09-08 2019-08-20 The Governement of the United States of America, as represented by the Secretary of Homeland Security Modified foot-and-mouth disease virus 3C proteases, compositions and methods thereof
JP2020500552A (ja) 2016-11-23 2020-01-16 グリットストーン オンコロジー インコーポレイテッド 新生抗原のウイルスによる送達方法
EP3634449A4 (en) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. ALPHAVIRUS NEOANTIGEN VECTORS
US20210330600A1 (en) 2018-12-21 2021-10-28 Tiba Biotech Llc Nanoparticle compositions for efficient nucleic acid delivery and methods of making and using the same
WO2021207020A1 (en) 2020-04-06 2021-10-14 Tiba Biotech Llc Carriers for efficient nucleic acid delivery
IL319926A (en) * 2021-03-19 2025-05-01 Tiba Biotech Llc Alphavirus-derived artificial RNA replicon expression systems

Similar Documents

Publication Publication Date Title
JP2024510610A5 (https=)
US20240042005A1 (en) Induce and enhance immune responses using recombinant replicon systems
Westaway et al. Togaviridae
JP7788787B2 (ja) 遺伝子発現増強のための組成物および方法
Pugachev et al. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection
JP2020500536A5 (https=)
CA2410948C (en) Method for the purification of alphavirus replicon particles
US6521235B2 (en) Alphavirus RNA replicon systems
JP2023541108A5 (https=)
JPH09511143A (ja) アルファーウイルスｃＤＮＡベクター
AU2004257214A1 (en) Alphavirus-based cytomegalovirus vaccines
US20210346492A1 (en) SARS-CoV-2 Vaccines
WO2022216574A1 (en) Calr and jak2 t-cell receptors
JP2019509750A5 (https=)
US20230398200A1 (en) Modified chikungunya viruses and sindbis viruses and uses thereof
JP2024535729A5 (https=)
US20260109975A1 (en) Self-replicating rna and use thereof
MXPA05012754A (es) Vacunas virales atenuadas vivas para virus de encefalitis equina oriental.
JP2025513827A5 (https=)
KR20230009324A (ko) 폴리뉴클레오타이드 및 이의 용도
WO2025157249A1 (zh) 一种自复制rna及其用途
US20250146038A1 (en) Methods for generating functional self-replicating rna molecules
Nagarajan et al. Self replicating gene vaccine carrying P1-2A gene of FMDV serotype O and its effects on the immune responses of cattle
Wang et al. A comprehensive review on COVID-19: What we know and how to treat against the novel coronavirus
JP2024539087A5 (https=)